Bayer AG is a Life Sciences & Agriculture company headquartered in Leverkusen, Germany. In FY2025, it reported $49.5B in site-standard revenue, based on official EUR45.6B native-currency revenue and a roughly $3.9B net loss. It had about 88,078 employees and is led by William N. (Bill) Anderson.
How Bayer Makes Money
Bayer makes money from prescription medicines, consumer self-care products, seeds, traits, herbicides, fungicides, insecticides, and digital agriculture tools. Its customers include patients, clinicians, pharmacies, health systems, consumers, growers, crop retailers, and agricultural distributors. The largest revenue driver is the Crop Science division, while Pharmaceuticals carries the highest strategic importance for long-term margin recovery.
Bayer Strategy
Bayer is focused on cost simplification through Dynamic Shared Ownership, disciplined capital allocation, pharmaceutical launch execution, and Crop Science margin recovery. The strategic focus is restoring cash generation while growing Nubeqa, Kerendia, Consumer Health brands, and resilient crop-science franchises.
Bayer Financials
Bayer's FY2025 dashboard reports EUR45.6B in group sales, EUR9.7B EBITDA before special items, a EUR3.6B net loss, EUR2.1B free cash flow, and EUR29.8B net financial debt. Bayer reported a FY2025 net loss of EUR3.6B, shown here as roughly a $3.9B net loss.
Bayer Competitive Position
Bayer's advantage is the combination of trusted health brands, global regulatory capabilities, seed and trait assets, and customer relationships across healthcare and agriculture. It competes with Pfizer, Novartis, Roche and other companies across Life Sciences & Agriculture.
Bayer Risks
Bayer's biggest risk is the combined pressure of Roundup litigation, net financial debt, crop-chemical price competition, and Xarelto patent erosion.
